A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

被引：0
|
作者：
Amy Y. Wang
Howard Weiner
Margaret Green
Hua Chang
Noreen Fulton
Richard A. Larson
Olatoyosi Odenike
Andrew S. Artz
Michael R. Bishop
Lucy A. Godley
Michael J. Thirman
Satyajit Kosuri
Jane E. Churpek
Emily Curran
Kristen Pettit
Wendy Stock
Hongtao Liu
机构：
[1] University of Chicago Medicine,Internal Medicine/Pediatric Residency Program
[2] University of Chicago Medicine,Department of Medicine, Section of Hematology/Oncology
[3] Karyopharm Therapeutics Inc,Department of Medicine, Section of Hematology/Oncology
[4] University of Michigan Medicine,undefined
来源：
Journal of Hematology & Oncology | / 11卷
关键词：
AML; Selinexor; Induction chemotherapy; XPO1/CRM1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] High-dose cytarabine benefits patients with acute myeloid leukemia and RAS mutations
    不详
    Nature Clinical Practice Oncology, 2009, 6 (1): : 3 - 4
  • [42] Phase I study of idarubicin dose escalation for remission induction therapy in acute myeloid leukemia
    Lee, Mark Hong
    Kim, Sung-Yong
    LEUKEMIA & LYMPHOMA, 2016, 57 (10) : 2268 - 2274
  • [43] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
    Lowenberg, Bob
    BLOOD, 2013, 121 (01) : 26 - 28
  • [44] A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
    Griffiths, Elizabeth A.
    Brady, William E.
    Tan, Wei
    Vigil, Carlos E.
    Thompson, James E.
    Ford, Laurie A.
    Dickey, Noelle M.
    Bashaw, Heather L.
    Sperrazza, Jill
    Wetzler, Meir
    Wang, Eunice S.
    LEUKEMIA RESEARCH, 2016, 43 : 44 - 48
  • [45] Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms
    Halpern, Anna B.
    Othus, Megan
    Huebner, Emily M.
    Scott, Bart L.
    Hendrie, Paul C.
    Percival, Mary-Elizabeth M.
    Becker, Pamela S.
    Smith, Heather A.
    Oehler, Vivian G.
    Orozco, Johnnie J.
    Cassaday, Ryan D.
    Gardner, Kelda M.
    Chen, Tara L.
    Buckley, Sarah A.
    Orlowski, Kaysey F.
    Anwar, Asma
    Estey, Elihu H.
    Walter, Roland B.
    HAEMATOLOGICA, 2019, 104 (04) : E143 - E146
  • [46] A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia
    DeAngelo, Daniel J.
    Brunner, Andrew M.
    Werner, Lillian
    Avigan, David
    Fathi, Amir T.
    Sperling, Adam S.
    Washington, Abigail
    Stroopinsky, Dina
    Rosenblatt, Jacalyn
    McMasters, Malgorzata
    Luptakova, Katarina
    Wadleigh, Martha
    Steensma, David P.
    Hobbs, Gabriela S.
    Attar, Eyal C.
    Amrein, Philip C.
    Ebert, Benjamin L.
    Stone, Richard M.
    Ballen, Karen K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (02) : 254 - 261
  • [47] Phase II study of high dose mitoxantrone-based induction therapy in patients with acute myeloid leukemia.
    Seiter, K
    Feldman, E
    Beer, M
    Qureshi, Z
    Durrani, H
    Lake, D
    Ahmed, T
    BLOOD, 1995, 86 (10) : 3106 - 3106
  • [48] Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics
    Ji-hao Zhou
    Hai-qing Lin
    Qi Shen
    Li-na Hu
    Guo-qiang Li
    Xiong-fei Sun
    Xin-you Zhang
    Current Medical Science, 2018, 38 : 51 - 57
  • [49] Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics
    Zhou, Ji-hao
    Lin, Hai-qing
    Shen, Qi
    Hu, Li-na
    Li, Guo-qiang
    Sun, Xiong-fei
    Zhang, Xin-you
    CURRENT MEDICAL SCIENCE, 2018, 38 (01) : 51 - 57
  • [50] Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics
    周继豪
    林海清
    沈琦
    胡丽娜
    李国强
    孙雄飞
    张新友
    Current Medical Science, 2018, (01) : 51 - 57
12345